Back to search

University of Southampton

Regulation of inflammatory responses in allergic asthma

Abstract

dc:description.abstract

<p><span >Allergic asthma is the result of a Th2-mediated immune response against allergens, with Th2 cytokines, such as IL-4, IL-5 and II,-13 playing a crucial role. T helper cells are thought to be able to cross-regulate each other and a number of possible treatments for allergic disorders have been tested in order to either potentiate Thl responses or block Th2 cytokines or their receptors. In my thesis I have sought to inhibit Th2 cytokine responses and, thereby, modulate allergic responses, using either cytokine inhibitors or microbial agents which are known to down-regulate cytokine responses.</span></p> <p><span >I have tested a soluble form of IL-4 receptor (sIL-4R) with the aim of blocking IL-4 and preventing the signalling cascade leading to cell activation and gene transcription. Recombinant human IL-4 caused an increase in IL-5 production by PBMC which peaked at 20 nM. sIL-4R caused a significant concentration-dependent inhibition of IL-5 secretion. The extent of inhibition with sIL-4R was comparable to that achieved by using anti IL-4 and IL-4R antibodies. Th2 down-regulation was not secondary to reduced survival of PBMC as tested in proliferation assays. Soluble IL-4R exerted a differential effect on Th2 and Th1 cytokines at low concentrations. It caused a significant (p<0.05) inhibition of <i>Der </i><i>p</i>-induced release of IL-5 at 1 µg/ml, without affecting IFN-</span>γ<span > production. A 2.6-fold increase in IFN-</span>γ<span > concentration was observed only when sIL-4R was used at 10 µg/ml, suggesting that inhibition of Th2 cytokines is not necessarily associated with promotion of Thl responses.</span></p> <p><span >To test the hypothesis that the non­-pathogenic <i>Mycobacterium vaccae </i>could reduce airway inflammation and the asthmatic reaction <i>in vivo </i>following allergen challenge and the Th2 response of <i>ex vivo </i>challenged PBMC, I conducted a clinical trial where an <i>M. vaccae </i>extract, SRL172, was administered intradermally. <i>M. vaccae </i>was able to cause a reduction in the late asthmatic response (LAR). During the LAR, the mean maximum fall in FEV<sub>1</sub> was 35.8% [16.5-66.7%] in subjects receiving SRL172 and 29.5% [16.9-39.4%] in subjects receiving placebo. In a subgroup of patients with mild asthma, <i>M. vaccae </i>caused a mean 47.2% relative reduction in the AUC of the LAR (p=0.026). However, the difference between treatment groups did not achieve statistical significance. Similarly, no difference was found in the early asthmatic response, (expressed as maximum % fall in either FEV<sub>1</sub> or AUC) and in PC<sub>20</sub>FEV<sub>1</sub> between the two treatment groups (p=0.98). Sputum analysis showed no difference in the differential cell count or in the levels of ECP and tryptase. Studies on peripheral blood mononuclear cells (PBMC) of these patients showed showed a trend towards reduction in IL-5 synthesis <i>in vitro </i>and serum IgE levels three weeks post-treatment with <i>M. vaccae </i>(p=0.07) but not placebo.</span></p>

Degree

thesis:*
Name dc:type.qualificationname
Ph.D.
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Southampton
Year dc:date.issued
2006

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Camporota, Luigi

Rights

Language dc:language
English, eng

Chain of custody

source
Harvested from
University of Southampton
Base URL
eprints.soton.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Camporota, Luigi. Regulation of inflammatory responses in allergic asthma. doctoral thesis, University of Southampton, 2006.